TY - JOUR
T1 - Interferon beta in the treatment of multiple sclerosis
T2 - Mechanisms of action
AU - Yong, V. Wee
AU - Chabot, Sophie
AU - Stuve, Olaf
AU - Williams, Gary
PY - 1998/9
Y1 - 1998/9
N2 - Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.
AB - Interferon beta (IFN-β) has been shown in several clinical trials to have efficacy in MS. Its mechanism of action, however, remains unclear. In this review, several biological activities of IFN-β are highlighted, including its inhibitory effects on proliferation of leukocytes and antigen presentation. Furthermore, IFN-β may modulate the profile of cytokine production toward that of the anti-inflammatory phenotype, and this appears to occur in the systemic circulation and within the CNS. Finally, IFN-β can reduce T-cell migration by inhibiting the activity of T-cell matrix metalloproteinases. These activities are likely to act in concert to account for the mechanism of IFN-β in MS.
UR - http://www.scopus.com/inward/record.url?scp=0008376732&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0008376732&partnerID=8YFLogxK
U2 - 10.1212/wnl.51.3.682
DO - 10.1212/wnl.51.3.682
M3 - Review article
C2 - 9748010
AN - SCOPUS:0008376732
VL - 51
SP - 682
EP - 689
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 3
ER -